Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Morphoregulatory ADD3 underlies glioblastoma growth and formation of tumor-tumor connections

ABSTRACT: Morphoregulatory ADD3 underlies glioblastoma growth and formation of tumor-tumor connections

PROVIDER: PRJNA1180487 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31179900_1.fastq.gz	Fastqsanger.gz
	SRR31179900_2.fastq.gz	Fastqsanger.gz
	SRR31179901_1.fastq.gz	Fastqsanger.gz
	SRR31179901_2.fastq.gz	Fastqsanger.gz
	SRR31179902_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Morphoregulatory ADD3 underlies glioblastoma growth and formation of tumor-tumor connections

Project description:Glioblastoma is a major unmet clinical need characterized by striking inter- and intra-tumoral heterogeneity and a population of glioblastoma stem cells (GSCs), conferring aggressiveness and therapy resistance. GSCs communicate through a network of tumor-tumor connections (TTCs), including nanotubes and microtubes, promoting tumor progression. However, very little is known about the mechanisms underlying TTC formation and overall GSC morphology. As GSCs closely resemble neural progenitor cells during neurodevelopment, we hypothesised that GSCs’ morphological features affect tumour progression. We identified GSC morphology as a new layer of tumoral heterogeneity with important consequences on GSC proliferation. Strikingly, we showed that the neurodevelopmental morphoregulator ADD3, is sufficient and necessary for maintaining proper GSC morphology, TTC abundance and cell cycle progression as well as required for cell survival. Remarkably, both the effects on cell morphology and proliferation depend on the stability of actin cytoskeleton. Hence, cell morphology and its regulators play a key role in tumor progression by mediating cell-cell communication. We thus propose that GSC morphological heterogeneity holds the potential to identify new therapeutic targets and diagnostic markers.

2024-11-12 | GSE280761 | GEO

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

Project description:Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy

| PRJNA688738 | ENA

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [B16F10]

Project description:Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [B16F10]

| PRJNA688741 | ENA

Targeting tumor-intrinsic neural vulnerabilities of glioblastoma

Project description:The neural behavior of glioblastoma, including the formation of tumor microtubes and synaptic circuitry, is increasingly understood to be pivotal for disease manifestation (Osswald et al. 2015; Venkatesh et al. 2015; Weil et al. 2017; Venkataramani et al. 2019; Venkatesh et al. 2019; Alcantara Llaguno et al. 2019; Venkataramani et al. 2022). Nonetheless, the few approved treatments for glioblastoma target its oncological nature, while its neural vulnerabilities remain incompletely mapped and clinically unexploited. Here, we systematically survey the neural molecular dependencies and cellular heterogeneity across 27 glioblastoma patients and diverse model systems. In patient tumor samples taken directly after surgery, we identify a spectrum of neural stem cell morphologies indicative of poor prognosis, and discover a set of repurposable neuroactive drugs with unexpected and consistent anti-glioma efficacy. Glioblastoma cells exhibit functional dependencies on highly expressed drug targets including neurological ion channels and receptors, while interpretable molecular machine learning reveals downstream convergence on secondary drug targets (COSTAR) involving AP-1-driven tumor suppression. COSTAR enables in silico drug screening on >1 million compounds that are validated with high accuracy. Multi-omic profiling of drug-treated glioblastoma cells confirms rapid Ca2+-driven AP-1 pathway induction to represent a tumor-intrinsic vulnerability at the intersection of oncogenesis and neural activity-dependent signaling. Finally, the consistent anti-glioma activity across patients and model systems is epitomized by the antidepressant Vortioxetine, which synergizes in vivo with approved glioblastoma chemotherapies. In all, our global analysis reveals that the neural vulnerabilities of glioblastoma converge on an AP-1 mediated gene regulatory network with direct translatable potential.

2024-08-01 | PXD037015 | panorama

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [T cells]

Project description:Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [T cells]

| PRJNA688742 | ENA

UTX condensation underlies its tumor suppressive activity

Project description:UTX condensation underlies its tumor suppressive activity

| PRJNA628656 | ENA

Proteomics of tumor associated microglia, tumor tissue from SB28 glioblastoma mice, and control microglia

Project description:The 18 kDa translocator protein (TSPO) emerges as an important PET biomarker to assess the tumor microenvironment (TME) in glioblastoma. However, various cellular sources hamper interpretation and biological understanding of TSPO and other immune biomarkers in the TME. Thus, we established a novel method, combining immunomagnetic cell sorting after radiotracer injection (scRadiotracing) with 3D histology via light sheet microscopy and proteomics to dissect cellular allocation of TSPO enrichment in glioblastoma. Single tumor cells of implanted SB28 glioblastoma mice indicated 1.37-fold higher TSPO tracer uptake and 1.46-fold higher TSPO protein expression levels when compared to tumor associated microglia/macrophages (TAMs). Using proteomics, we compared the proteome of tumor associated microglia/macrophages (TAMs), Tumor tissue (TT) and control microglia from WT mice without glioblastoma. This analysis identified TAM specific targets for PET radioligand development with additional potential to monitor diverse TAM subpopulations in vivo. In summary, our data indicate that tumor cells need to be acknowledged as the main contributor to TSPO as a biomarker in glioblastoma. Combining cellular tracer uptake measures with 3D histology facilitates precise allocation of complex PET signal sources and will serve to validate novel TAM specific radioligands.

2023-10-30 | PXD044033 | Pride

CD15-positive tumor-derived glioblastoma cells

Project description:CD15-positive tumor-derived glioblastoma cells

| PRJNA401001 | ENA

Extreme structural heterogeneity rewires glioblastoma chromosomes to sustain patient-specific transcriptional programs [WGS]

Project description:Glioblastoma multiforme encompasses a range of brain malignancies marked by phenotypic and transcriptional heterogeneity, which is thought to render these tumors aggressive, resistant to therapy, and inevitably recurrent. However, little is known about how the spatial organization of glioblastoma genomes underlies this heterogeneity and its effects. We compiled a cohort of 28 patient-derived glioblastoma stem-like lines (GSCs) known to reflect the properties of their tumor-of-origin; six of these came from primary-relapse tumor pairs in the same patient. We generated and analyzed kbp-resolution whole-genome chromosome conformation capture (Hi-C) data from all GSCs to systematically map >3,100 structural variants (SVs) and >6,300 neoloops. By combining Hi-C, histone modification, and gene expression data with 3D chromatin folding simulations, we explain how the pervasive, uneven, and idiosyncratic occurrence of neoloops sustains tumor-specific transcriptional programs via the formation of new enhancer-promoter contacts. We also exemplify how neoloops, albeit scarcely recurring, can help us infer potential patient-specific vulnerabilities. Thus, our data serve as a resource for dissecting glioblastoma biology and heterogeneity, as well as for informing therapeutic approaches.

2024-04-11 | GSE263685 | GEO

Extreme structural heterogeneity rewires glioblastoma chromosomes to sustain patient-specific transcriptional programs [RNA-Seq]

2024-03-19 | GSE229965 | GEO